This Phase II study evaluates the efficacy of pembrolizumab, an established PD-1 inhibitor, in a neoadjuvant setting for patients with MMR-deficient localized colon cancer. The trial's completion and anticipated results could position pembrolizumab as a key treatment option in early-stage dMMR colon cancer, potentially expanding its market share in colorectal cancer therapies. The competitive landscape includes other immunotherapies and emerging agents targeting similar pathways, necessitating a thorough analysis of clinical outcomes and safety profiles. Given the growing interest in personalized medicine and immunotherapy, successful results may enhance pembrolizumab's market positioning and lead to further indications, impacting future pricing and reimbursement strategies.